Ethics in Transplantation

Dec 5, 2013 1:00pm ‐ Dec 5, 2013 2:00pm

Identification: WEB131205

Credits: None available.


Pathology

Feb 21, 2014 4:00pm ‐ Feb 21, 2014 5:00pm

Identification: WEB140221

Credits: None available.

Explore cases in kidney, liver, and heart where the pathology indicated rejection, but where another diagnosis was ultimately identified.

Kidney:
Naima Carter-Monroe, MD, MHS • Johns Hopkins University School of Medicine
Lorraine Racusen, MD, FASN • Johns Hopkins University School of Medicine

Heart:
E. Rene Rodriguez, MD • Cardiovascular Pathology, The Cleveland Clinic

Liver:
Nitika Gupta, MD, DCH, DNB, MRCPCH • Emory University School of Medicine
Murli Krishna, MD • Mayo Clinic, Jacksonville


The Future of Translational Research

Mar 20, 2014 3:00pm ‐ Mar 20, 2014 4:00pm

Identification: WEB140320

Credits: None available.

Learning objectives:

  • To define translational research
  • To be able to explain 3 strengths and weaknesses of team science in transplantation
  • To elucidate the requirements for performing laboratory studies using human samples obtained from clinical trials in so as to be able to make interpretable conclusions
  • To be able to communicate a testable hypothesis relevant for clinical/translational research in transplantation

Generic Immunosuppressants: Good Medicine or a Cheap Fix?

Apr 10, 2014 12:00pm ‐ Apr 10, 2014 1:00pm

Identification: WEB140410

Credits: None available.

There currently are more than 20 generic formulations of different immunosuppressant medications used in transplantation that are approved for use on the US market. Therefore, questions have been raised as to the safety and efficacy of generic substitution in the transplant community. The objective of the webinar is to provide an overview of the generic medication approval process and its applicability to immunosuppressants used in solid organ transplant. We will also discuss the safety and efficacy of generic conversion from brand and interchangeability of different generic immunosuppressants from both pharmacokinetic and clinical trial data.

Should I Accept this Donor?

May 7, 2014 1:00pm ‐ May 7, 2014 2:00pm

Identification: WEB140507

Credits: None available.

Learning objectives:

  1. Explain donor characteristics that raise concern for increased risk of recent HIV, hepatitis B and/or hepatitis C infection
  2. Explain how to approach donors with death from encephalitis of unknown etiology
  3. Discuss clues to raise concern for other transmissible infections in donors and how to manage the recipient postoperatively when the organs are accepted
  4. Discuss the risk-benefit of accepting vs discarding organs for certain donor-recipient scenarios
  5. Explain how to manage recipients of organs from donors with bacteremia or other bacterial infections.

Malignancies after Solid Organ Transplantation

Jun 4, 2014 1:00pm ‐ Jun 4, 2014 2:00pm

Identification: WEB140604

Credits: None available.

Exposure to immunosuppressive drugs increases the risk of malignancy in transplant recipients. The risk of malignancy varies by organ type, duration and intensity of immunosuppression, recipient age, and exposure to oncogenic viruses. Participants in this session will gain an understanding of the pathophysiology of malignancy in the transplant recipient and apply this knowledge to identify patients at high risk, develop preventative strategies to mitigate risk, ensure timely diagnosis and optimize the treatment of recipients with post transplant malignancy.